Table 3.
Drug-drug interactions (DDIs) in NH residents according CheckTheMeds software a.
| Potential Outcome | Number of DDIs | Severity of DDIs and Pairs of Drugs Involved |
|---|---|---|
| Central nervous system depression | 167 (47.6%) | Moderate: Benzodiazepine + trazodone (13); Benzodiazepine + mirtazapine (13); Benzodiazepine + venlafaxine (8) |
| QT prolongation | 11 + 53 = 64 (18.2%) | Severe: SSRI + quetiapine (5) Moderate: SSRI + trazodone (10); SSRI + mirtazapine (8) |
| Respiratory depression | 22 (6.3%) | Moderate: Benzodiazepine + opioid (21) |
| CYP enzyme inhibitor | 9 (2.6%) | Moderate: Omeprazole + citalopram (4); Omeprazole + gliclazide (3) |
| Serotonin syndrome | 3 + 5 = 8 (2.3%) | Severe: Rasagiline + antidepressants (2) Moderate: Escitalopram + amitriptyline (2) |
| Increased bleeding risk | 6 (1.7%) | Moderate: Allopurinol + acenocoumarol (4); NSAIDs + acenocoumarol (2) |
| Increased adverse reactions NSAIDs | 5 (1.4%) | Moderate: corticoids/SSRI + NSAIDs (5) |
| Triple whammy | 3 (0.9%) | Moderate: ACEI/ARBs + diuretic + NSAIDs (3) |
| Anticholinergic risk | 1 + 1 = 2 (0.6%) | Severe: Tolterodine + ipratropium (1) Moderate: Tolterodine + baclofen (1) |
| Other | 65 (18.5%) | |
| Severe DDIs | 26 (7.4%) | |
| Moderate DDIs | 325 (92.6%) | |
| Total DDIs | 351 (100%) |
a In some rows only the most frequent DDIs are shown.